Advertisement
Canada markets open in 3 hours 22 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7310
    +0.0013 (+0.17%)
     

  • CRUDE OIL

    82.76
    -0.05 (-0.06%)
     

  • Bitcoin CAD

    87,377.34
    -3,518.38 (-3.87%)
     

  • CMC Crypto 200

    1,360.57
    -22.00 (-1.59%)
     

  • GOLD FUTURES

    2,336.80
    -1.60 (-0.07%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,512.75
    -151.75 (-0.86%)
     

  • VOLATILITY

    16.16
    +0.19 (+1.19%)
     

  • FTSE

    8,098.89
    +58.51 (+0.73%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6813
    -0.0006 (-0.09%)
     

Nexstim Plc annuls stock options held by the company

Nexstim Oyj
·2 min read

Company announcement, Helsinki, 8 November 2021 at 3 PM (EET)

Nexstim Plc annuls stock options held by the company

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that its Board of Directors has resolved in its meeting on November 8, 2021 on annulment of in total 2,169 option rights 2020A which have been returned to the possession of the Company due to ended employments. Pursuant to the annulment, no option rights in this plan 2020A remain in the possession of the Company.

Further information is available on the website www.nexstim.com, or by contacting:

Leena Niemistö, Chair of Board of Directors
+358 9 2727 170
leena.niemisto@nexstim.com

ADVERTISEMENT

Erik Penser Bank AB (Certified Advisor))
+46 8 463 8300
certifiedadviser@penser.se

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com

Attachment